The stock of Avalanche Biotechnologies Incorporated (NASDAQ:AAVL) registered a decrease of 8.17% in short interest. AAVL’s total short interest was 1.27 million shares in April as published by FINRA. Its down 8.17% from 1.39M shares, reported previously. With 371,700 shares average volume, it will take short sellers 3 days to cover their AAVL’s short positions. The short interest to Avalanche Biotechnologies Incorporated’s float is 9.99%. The stock decreased 1.70% or $0.09 on April 8, hitting $5.2. Avalanche Biotechnologies Inc (NASDAQ:AAVL) has declined 51.13% since September 2, 2015 and is downtrending. It has underperformed by 56.19% the S&P500.
Avalanche Biotechnologies, Inc. is a clinical-stage biotechnology company. The company has a market cap of $137.30 million. The Firm is focused on discovering and developing gene therapies for patients with sight-threatening ophthalmic diseases. It currently has negative earnings. The Firm uses its gene therapy platform, the Ocular BioFactory, to create a pipeline of product candidates.
The institutional sentiment decreased to 1.13 in 2015 Q3. Its down 0.30, from 1.43 in 2015Q2. The ratio dropped, as 24 funds sold all Avalanche Biotechnologies Inc shares owned while 24 reduced positions. 18 funds bought stakes while 36 increased positions. They now own 24.13 million shares or 54.28% more from 15.64 million shares in 2015Q2.
Vhcp Management Llc holds 2.92% of its portfolio in Avalanche Biotechnologies Inc for 1.38 million shares. Green Owl Capital Management Llc owns 250,000 shares or 1.6% of their US portfolio. Moreover, Dafna Capital Management Llc has 1.15% invested in the company for 140,600 shares. The Texas-based Wildcat Capital Management Llc has invested 0.77% in the stock. Cadian Capital Management Lp, a New York-based fund reported 1.48 million shares.
Out of 3 analysts covering Avalanche Biotechnologies (NASDAQ:AAVL), 3 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $15 is the highest target while $9 is the lowest. The $12 average target is 236.54% above today’s ($5.2) stock price. Avalanche Biotechnologies was the topic in 5 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Chardan Capital Markets upgraded the stock on August 17 to “Buy” rating.
Avalanche Biotechnologies Inc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.